Compare NEN & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
New England Realty Associates Limited Partnership Depositary Receipts Evidencing Units of Limited Partnership
Current Price
Current Price
| Metric | NEN | CGEN |
|---|---|---|
| Founded | 1977 | 1993 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Building operators | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 197.0M | 201.8M |
| IPO Year | 1995 | 2001 |
| Metric | NEN | CGEN |
|---|---|---|
| Price | $44.00 | $2.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $4.80 |
| AVG Volume (30 Days) | 1.2K | ★ 229.9K |
| Earning Date | 11-13-2026 | 11-09-2026 |
| Dividend Yield | ★ 3.61% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $89,196,544.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $55.33 |
| P/E Ratio | $19.68 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $44.24 | $1.43 |
| 52 Week High | $71.07 | $3.24 |
| Indicator | NEN | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 32.93 | 49.52 |
| Support Level | N/A | $1.98 |
| Resistance Level | $66.30 | $2.33 |
| Average True Range (ATR) | 0.63 | 0.09 |
| MACD | -0.06 | 0.03 |
| Stochastic Oscillator | 0.00 | 73.68 |
New England Realty Associates LP is engaged in the business of acquiring, developing, holding for investment, operating, and selling real estate. The Partnership owns and operates various residential apartments, condominium units, and commercial properties located in Massachusetts and New Hampshire. The company generates revenue from rental income from residential and commercial properties recognized over the term of the related lease. The long-term goals of the Partnership are to manage, rent, and improve its properties and to acquire additional properties with income and capital appreciation potential as suitable opportunities arise.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.